Quality of life in patients with gastroenteropancreatic tumours: A systematic literature review

Table 3 The specific domain scores reported in the literature for gastroenteropancreatic neuroendocrine tumours patients using QLQ-GI.NET21

Ref.	Intervention/ comparator	Time point	Endocrine Symptoms	Gastrointestinal Symptoms	Social function	Disease related worries	Muscle/bone pain symptom	Weight gain	Information/Communication function	Body Image	Sexual function	Treatment related symptoms scale
Ramage et al[54], 2019	Everolimus	Baseline (paired scores with 3 mo)	14.8	24.4	44.1	51.1	35.2	NR	1.9	25.9	37	NA
		3 mo	12.3	20.2	42.6	44.8	35.2	NR	4.6	24.1	42.6	22
		Baseline (paired scores with 6 mo)	14.4	25.8	44.8	50.9	33.3	NR	1.1	20	35.6	NA
		6 mo	12.6	21.8	34.4	43.7	30	NR	1.1	21.1	37.8	14.1
Lewis et al[3], 2018	NA	Single timepoint (patients without CS)	16.7	18.9	60.0	56.9	41.3	18.7	10.7	15.3	60.8	17.5
		Single timepoint (patients with CS)	28.4	24.0	68.4	38.7	46.7	13.3	16.0	13.3	68.4	10.1
Yadegarfar et al[33], 2013	Various	Baseline (P-NETs)	22	26	39	56	25	11	10	25	32	18
		3 mo (P-NETs)	16	18	33	44	31	9	4	21	31	22
		6 mo (P-NETs)	18	22	30	50	32	13	10	19	31	23
Ballal et al[8], 2019	225Ac-DOTATATE TAT	Baseline	21.4	40.2	64.3	61.2	38.8	25	NR	28.8	40	6.53
		End of assessment	3.57	22.8	72.9	84.2	26.8	27.8	NR	15.6	45	26.24
Strosberg et al[17], 2018	177Lu-DOTATATE	Baseline	NR	22.8	33.4	43.7	29	NR	5.4	20	30.6	11.6
	High-dose octreotide	Baseline	NR	23.8	37.1	43.8	34.6	NR	12.3	20.3	28.2	11.9
Cella et al[44], 2018	Telotristat ethyl	Baseline (Durable responders)	37.8	33.8	46.7	41.1	35	NR	5	29.1	47.2	18.1
		Baseline (Nondurable responders)	29.5	28.5	38.5	37.6	30.3	NR	7	26.9	32.6	12.8
		Difference in change from baseline between subpopulations	-1.9	-9.6	-2.8	1.9	-4.5	NR	3.9	1	-1.6	-3.4

NA: Not available; P-NET: Pancreas-neuroendocrine tumours; CS: Carcinoid syndrome; NR: Not relevant.